Morepen Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 26, 2026, recommended Final Dividend of Rs. 0.20 per equity share.
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Morepen Laboratories' Board approved Q4 and FY2026 audited results showing standalone net profit of Rs. 6,605.75 Lakhs with EPS of Rs. 1.21, and consolidated net profit of Rs. 11,992.00 Lakhs with EPS of Rs. 2.20. The Board recommended a final dividend of Rs. 0.20 per equity share (face value Rs. 2 each) for FY2026, subject to shareholder approval at the AGM. The company also executed a second addendum to its Business Transfer Agreement with subsidiary Morepen Medipath Limited, revising the appointed date for transfer of the Medical Devices business to April 1, 2026, with lump-sum consideration of Rs. 19,710.12 Lakhs. Statutory auditors issued an unmodified opinion on the financial statements.
The modest Rs. 0.20 per share dividend reflects the company's conservative approach, while the business transfer agreement represents an internal reorganization of the medical devices segment into its subsidiary. The transfer price of Rs. 19,710.12 Lakhs (approximately Rs. 197 crore) represents a related-party transaction being conducted at arm's length.